The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo

Prostate

Volumn 73, Issue 5, 2013, Pages 489-499

  Abedinpour, Parisa ^a   Baron, Véronique T ^a   Chrastina, Adrian ^a,b   Welsh, John ^a   Borgström, Per ^a  

^a Vaccine Research Institute of San Diego   (United States)

^b Proteogenomics Research Institute for Systems Medicine   (United States)

Author keywords

androgen therapy; combination therapy; dorsal chamber model; intra vital microscopy; plumbagin; prostate cancer

Indexed keywords

ANDROGEN; PLUMBAGIN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CASTRATION; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; TREATMENT PLANNING; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; G2 PHASE CELL CYCLE CHECKPOINTS; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; NAPHTHOQUINONES; NEOPLASM TRANSPLANTATION; ORCHIECTOMY; REACTIVE OXYGEN SPECIES; SKIN;

EID: 84875134252     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22585     Document Type: Article

References (55)

1. Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF,. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU Int; 2012; 109 (7): 968-985.
2. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ,. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31 (5): 578-583.
3. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin WP, Wei JT,. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005; 23 (12): 2772-2780.
4. Higano CS, Crawford ED,. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol 2011; 29 (6 Suppl) S1-S8.
5. Padhye S, Dandawate P, Yusufi M, Ahmad A, Sarkar FH,. Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev 2010; PMID: 21064184.
6. Aziz MH, Dreckschmidt NE, Verma AK,. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res 2008; 68 (21): 9024-9032.
7. Powolny AA, Singh SV,. Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm Res 2008; 25 (9): 2171-2180.
8. Lai L, Liu J, Zhai D, Lin Q, He L, Dong Y, Zhang J, Lu B, Chen Y, Yi Z, Liu M,. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. Br J Pharmacol 2012; 165 (4b): 1084-1096.
9. Devi PU, Rao BS, Solomon FE,. Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse Ehrlich as cites carcinoma in vivo. Indian J Exp Biol 1998; 36 (9): 891-895.
10. Devi PU, Solomon FE, Sharada AC,. In vivo tumor inhibitory and radiosensitizing effects of an Indian medicinal plant, Plumbago rosea on experimental mouse tumors. Indian J Exp Biol 1994; 32 (8): 523-528.
11. Nair S, Nair RR, Srinivas P, Srinivas G, Pillai MR,. Radiosensitizing effects of plumbagin in cervical cancer cells is through modulation of apoptotic pathway. Mol Carcinog 2008; 47 (1): 22-33.
12. Prasad VS, Devi PU, Rao BS, Kamath R,. Radiosensitizing effect of plumbagin on mouse melanoma cells grown in vitro. Indian J Exp Biol 1996; 34 (9): 857-858.
13. Li J, Shen Q, Peng R, Chen R, Jiang P, Li Y, Zhang L, Lu J,. Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells. J Huazhong Univ Sci Technol Med Sci 2010; 30 (4): 458-463.
14. Baron VT, Welsh J, Abedinpour P, Borgstrom P,. Intravital microscopy in the mouse dorsal chamber model for the study of solid tumors. Am J Cancer Res 2011; 1 (5): 674-686.
15. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H,. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007; 67 (13): 6083-6091.
16. Frost GI, Dudouet B, Lustgarten J, Borgstrom P,. The roles of epithelial-mesenchymal interactions and the innate immune response on the tumorigenicity of human prostate carcinoma cell lines grown in immuno-compromised mice. In vivo (Athens, Greece) 2003; 17 (5): 377-388.
17. Frost GI, Lustgarten J, Dudouet B, Nyberg L, Hartley-Asp B, Borgstrom P,. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration. Microvasc Res 2005; 69 (1/2): 1-9.
18. Oh P, Borgstrom P, Witkiewicz H, Li Y, Borgstrom BJ, Chrastina A, Iwata K, Zinn KR, Baldwin R, Testa JE, Schnitzer JE,. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol 2007; 25 (3): 327-337.
19. Funk W, Endrich B, Messmer K,. A novel method for follow-up studies of the microcirculation in non-malignant tissue implants. Res Exp Med 1986; 186 (4): 259-270.
20. Langer S, Sinitsina I, Biberthaler P, Krombach F, Messmer K,. Revascularization of transplanted adipose tissue: a study in the dorsal skinfold chamber of hamsters. Ann Plast Surg 2002; 48 (1): 53-59.
21. Laschke MW, Elitzsch A, Scheuer C, Holstein JH, Vollmar B, Menger MD,. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 2006; 149 (2): 137-144.
22. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD,. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod (Oxford, England) 2006; 21 (1): 262-268.
23. Abedinpour P, Baron VT, Welsh J, Borgstrom P,. Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo. Prostate 2011; 71 (8): 813-823.
24. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H,. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4 (3): 209-221.
25. Kanda T, Sullivan KF, Wahl GM,. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol 1998; 8 (7): 377-385.
26. Klaus V, Hartmann T, Gambini J, Graf P, Stahl W, Hartwig A, Klotz LO,. 1,4-Naphthoquinones as inducers of oxidative damage and stress signaling in HaCaT human keratinocytes. Arch Biochem Biophys 2010; 496 (2): 93-100.
27. Ollinger K, Brunmark A,. Effect of hydroxy substituent position on 1,4-naphthoquinone toxicity to rat hepatocytes. J Biol Chem 1991; 266 (32): 21496-21503.
28. Mohler JL,. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008; 617: 223-234.
29. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI,. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28 (9): 1496-1501.
30. Nazeem S, Azmi AS, Hanif S, Ahmad A, Mohammad RM, Hadi SM, Kumar KS,. Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. Mutagenesis 2009; 24 (5): 413-418.
31. Bachur NR, Gordon SL, Gee MV,. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 1978; 38 (6): 1745-1750.
32. Imlay J, Fridovich I,. Exogenous quinones directly inhibit the respiratory NADH dehydrogenase in Escherichia coli. Arch Biochem Biophys 1992; 296 (1): 337-346.
33. Inbaraj JJ, Chignell CF,. Cytotoxic action of juglone and plumbagin: a mechanistic study using HaCaT keratinocytes. Chem Res Toxicol 2004; 17 (1): 55-62.
34. Kawiak A, Piosik J, Stasilojc G, Gwizdek-Wisniewska A, Marczak L, Stobiecki M, Bigda J, Lojkowska E,. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol Appl Pharmacol 2007; 223 (3): 267-276.
35. Srinivas P, Gopinath G, Banerji A, Dinakar A, Srinivas G,. Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog 2004; 40 (4): 201-211.
36. Wang CC, Chiang YM, Sung SC, Hsu YL, Chang JK, Kuo PL,. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett 2008; 259 (1): 82-98.
37. Kuo PL, Hsu YL, Cho CY,. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 2006; 5 (12): 3209-3221.
38. O'Brien PJ,. Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact 1991; 80 (1): 1-41.
39. Brigelius-Flohe R, Kipp A,. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta 2009; 1790 (11): 1555-1568.
40. Lau AT, Wang Y, Chiu JF,. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem 2008; 104 (2): 657-667.
41. Ahmad A, Banerjee S, Wang Z, Kong D, Sarkar FH,. Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kappaB and Bcl-2. J Cell Biochem 2008; 105 (6): 1461-1471.
42. Singh UV, Udupa N,. Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich as cites carcinoma. Indian J Physiol Pharmacol 1997; 41 (2): 171-175.
43. Krishnaswamy M, Purushothaman KK,. Plumbagin: a study of its anticancer, antibacterial & antifungal properties. Indian J Exp Biol 1980; 18 (8): 876-877.
44. Premakumari P, Rathinam K, Santhakumari G,. Antifertility activity of plumbagin. Indian J Med Res 1977; 65 (6): 829-838.
45. Liu H, Colavitti R, Rovira II, Finkel T,. Redox-dependent transcriptional regulation. Circ Res 2005; 97 (10): 967-974.
46. Gomathinayagam R, Sowmyalakshmi S, Mardhatillah F, Kumar R, Akbarsha MA, Damodaran C,. Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res 2008; 28 (2A): 785-792.
47. Sandur SK, Ichikawa H, Sethi G, Ahn KS, Aggarwal BB,. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 2006; 281 (25): 17023-17033.
48. Hsu YL, Cho CY, Kuo PL, Huang YT, Lin CC,. Plumbagin (5-hydroxy-2-methyl- 1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther 2006; 318 (2): 484-494.
49. Checker R, Sharma D, Sandur SK, Subrahmanyam G, Krishnan S, Poduval TB, Sainis KB,. Plumbagin inhibits proliferative and inflammatory responses of T cells independent of ROS generation but by modulating intracellular thiols. J Cell Biochem 2010; 110 (5): 1082-1093.
50. Shieh JM, Chiang TA, Chang WT, Chao CH, Lee YC, Huang GY, Shih YX, Shih YW,. Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-kappaB and AP-1 via ERK signaling pathway in A549 human lung cancer cells. Mol Cell Biochem 2010; 335 (1/2): 181-193.
51. Yang SJ, Chang SC, Wen HC, Chen CY, Liao JF, Chang CH,. Plumbagin activates ERK1/2 and Akt via superoxide, Src and PI3-kinase in 3T3-L1 cells. Eur J Pharmacol 2010; 638 (1-3): 21-28.
52. Sun J, McKallip RJ,. Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression. Leukemia Res 2011; 35 (10): 1402-1408.
53. Xu KH, Lu DP,. Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo. Leukemia Res 2010; 34 (5): 658-665.
54. Buttyan R, Ghafar MA, Shabsigh A,. The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol 2000; 10 (5): 415-420.
55. Woodward WA, Wachsberger P, Burd R, Dicker AP,. Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. Prostate Cancer Prostatic Dis 2005; 8 (2): 127-132.